"Toll-Like Receptor 2" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A pattern recognition receptor that forms heterodimers with other TOLL-LIKE RECEPTORS. It interacts with multiple ligands including PEPTIDOGLYCAN, bacterial LIPOPROTEINS, lipoarabinomannan, and a variety of PORINS.
| Descriptor ID |
D051195
|
| MeSH Number(s) |
D12.776.543.750.705.910.500.200
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Toll-Like Receptor 2".
Below are MeSH descriptors whose meaning is more specific than "Toll-Like Receptor 2".
This graph shows the total number of publications written about "Toll-Like Receptor 2" by people in this website by year, and whether "Toll-Like Receptor 2" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2005 | 0 | 2 | 2 |
| 2006 | 0 | 1 | 1 |
| 2008 | 1 | 1 | 2 |
| 2009 | 2 | 0 | 2 |
| 2010 | 0 | 1 | 1 |
| 2011 | 2 | 2 | 4 |
| 2012 | 2 | 0 | 2 |
| 2013 | 0 | 1 | 1 |
| 2014 | 2 | 1 | 3 |
| 2015 | 2 | 1 | 3 |
| 2016 | 1 | 0 | 1 |
| 2017 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Toll-Like Receptor 2" by people in Profiles.
-
Hardigan T, Hernandez C, Ward R, Hoda MN, Ergul A. TLR2 knockout protects against diabetes-mediated changes in cerebral perfusion and cognitive deficits. Am J Physiol Regul Integr Comp Physiol. 2017 06 01; 312(6):R927-R937.
-
Hardigan T, Abdul Y, Ergul A. Linagliptin reduces effects of ET-1 and TLR2-mediated cerebrovascular hyperreactivity in diabetes. Life Sci. 2016 Aug 15; 159:90-96.
-
Mehmeti M, Allaoui R, Bergenfelz C, Saal LH, Ethier SP, Johansson ME, Jirström K, Leandersson K. Expression of functional toll like receptor 4 in estrogen receptor/progesterone receptor-negative breast cancer. Breast Cancer Res. 2015 Sep 22; 17:130.
-
Denlinger CE. Toll-like receptor 4 inhibition in lung ischemia-reperfusion injury: Time for a clinical trial? J Thorac Cardiovasc Surg. 2015 Jun; 149(6):1662-3.
-
Liang Q, Dong S, Lei L, Liu J, Zhang J, Li J, Duan J, Fan D. Protective effects of Sparstolonin B, a selective TLR2 and TLR4 antagonist, on mouse endotoxin shock. Cytokine. 2015 Oct; 75(2):302-9.
-
Karumuthil-Melethil S, Sofi MH, Gudi R, Johnson BM, Perez N, Vasu C. TLR2- and Dectin 1-associated innate immune response modulates T-cell response to pancreatic ß-cell antigen and prevents type 1 diabetes. Diabetes. 2015 Apr; 64(4):1341-57.
-
Liu Q, Li J, Jubair S, Wang D, Luo Y, Fan D, Janicki JS. Sparstolonin B attenuates hypoxia-induced apoptosis, necrosis and inflammation in cultured rat left ventricular tissue slices. Cardiovasc Drugs Ther. 2014 Oct; 28(5):433-9.
-
Liu Q, Wang J, Liang Q, Wang D, Luo Y, Li J, Janicki JS, Fan D. Sparstolonin B attenuates hypoxia-reoxygenation-induced cardiomyocyte inflammation. Exp Biol Med (Maywood). 2014 Mar; 239(3):376-84.
-
Jin J, Zhang X, Lu Z, Perry DM, Li Y, Russo SB, Cowart LA, Hannun YA, Huang Y. Acid sphingomyelinase plays a key role in palmitic acid-amplified inflammatory signaling triggered by lipopolysaccharide at low concentrations in macrophages. Am J Physiol Endocrinol Metab. 2013 Oct 01; 305(7):E853-67.
-
Li P, Neubig RR, Zingarelli B, Borg K, Halushka PV, Cook JA, Fan H. Toll-like receptor-induced inflammatory cytokines are suppressed by gain of function or overexpression of Ga(i2) protein. Inflammation. 2012 Oct; 35(5):1611-7.